克洛沙平监测:形式遵循功能
Abigail L Donovan1,2, Cheryl Y S Foo1,2, Carol Lim1,2
1Psychosis Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston.
Psychiatric services (Washington, D.C.)
|March 17, 2026
概括
克洛沙平的REMS程序已经消失,允许使用新的监测系统. 该系统使用了三阶段框架,共享决策,用于克洛扎治疗.
科学领域:
- 精神病学和药理学 精神病学和药理学
- 处理监控系统 处理监控系统
背景情况:
- 克洛扎风险评估和缓解策略 (REMS) 计划已被取消.
- 这种消除使得需要修订克洛扎的监测方法.
研究的目的:
- 为克洛扎监测提出一个新的概念框架.
- 通过分阶段治疗模式,整合医疗和精神病治疗.
主要方法:
- 拟议的系统分为三个不同的阶段:克洛扎宾试验,治疗优化和治疗巩固.
- 每个阶段都有特定的治疗目标和监测时间表.
- 涉及处方者,患者和家庭/监护人的共同决策是每个阶段启动的核心.
主要成果:
- 新的框架促进了对克洛扎管理的结构化方法.
- 反向医疗-精神病学整合在整个治疗阶段都被纳入.
- 建立治疗决策点来评估治疗选择.
结论:
- 拟议的三阶段监测系统为以前的克洛扎REMS计划提供了一个结构化的替代方案.
- 这种模式强调综合护理和以患者为中心的决策,用于克洛沙平治疗.
- 该框架支持优化和整合的克洛扎治疗.
相关概念视频
Psychosis: Goals of Pharmacotherapy
653
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
653
Drug Therapy
376
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
376
Psychosis and Antipsychotic Drugs: Overview
1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Antipsychotic Drugs: Typical and Atypical Agents
1.2K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.2K
Antipsychotic Drugs: Therapeutic Uses and Side Effects
1.1K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.1K
Therapeutic Drug Monitoring: Affecting Factors
316
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
316


